

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

Title: Smoking, e-cigarettes and the effect on respiratory symptoms among a population sample of youth: retrospective study.

Authors: Chaiton M PhD^{1,2}, Pienkowski M BSc¹, Musani I MPH¹, Bondy SJ PhD¹, Cohen JE PhD³, Dubray J MSc¹, Eissenberg TE PhD⁴, Kaufman P PhD¹, Stanbrook MB MD PhD⁵, Schwartz R PhD^{1,2}.

¹Dalla Lana School of Public Health, University of Toronto, Canada; ²Centre for Addiction and Mental Health, Toronto, Canada; ³Institute for Global Tobacco Control, Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; ⁴Department of Psychology, Virginia Commonwealth University; ⁵Division of Respiriology, Department of Medicine, University of Toronto, Canada.

Corresponding Author:

Michael Chaiton
Ontario Tobacco Research Unit
Centre for Addiction and Mental Health
155 College St.
Toronto, Ontario, M5T 3M7
Tel: 416-978-7096
Fax: 416-595-6068
[Email: michael.chaiton@camh.ca](mailto:michael.chaiton@camh.ca)

Word count: 2659

Contributors

Guarantor: Michael Chaiton takes responsibility for (is the guarantor of) the content of the manuscript, including the data and analysis.

Financial disclosure Dr. Eissenberg is a paid consultant in litigation against the tobacco industry and also the electronic cigarette industry and is named on one patent for a device that measures the puffing behavior of electronic cigarette users and on another patent for a smartphone app that determines electronic cigarette device and liquid characteristics. Other authors have no disclosures to report.

Conflict of interests/The CSTP is supported by grant number U54DA036105 from the National Institute on Drug Abuse of the National Institutes of Health and the Center for Tobacco Products of the U.S. Food and Drug Administration. The content of this message is solely the responsibility of the author and does not necessarily represent the views of the NIH or the FDA. The cohort study was funded by CIHR. The funding sources had no role in the study design, collection, analysis, and interpretation of data, writing the report and the decision to submit the report for publication.

Data sharing: De-identified participant data can be made available upon request to researchers with permission from an academic ethics review board.

46 **Abstract**

47 **Introduction:** E-cigarettes have been steadily increasing in popularity, both as cessation
48 methods for smoking and for recreational and social reasons. This increase in vaping may pose
49 cardiovascular and respiratory risks. We aimed to assess respiratory symptoms in youth users of
50 e-cigarettes and cigarettes.

51 **Methods:** A cross-sectional survey design was utilized to assess Canadian youth aged 16-25
52 years old. Participants were recruited from the Ontario Tobacco Research Unit Youth and Young
53 Adult Research Registration Panel November 2020 to March 2021. A total of 3,082 subjects
54 completed the baseline survey. Of these, 2660 individuals who did not have asthma were
55 included in the analysis. The exposure of interest was vaping dose, pack equivalent years,
56 equivalent to cigarette pack years incorporating number of puffs per day, number of days vaped
57 per month, and number of years vaped. Respiratory symptoms were measured using the five-
58 item Canadian Lung Health Test. Poisson regression analyses were performed while adjusting
59 for demographic confounders, stratified by smoking status. A non-stratified model tested the
60 interaction of status and vaping dose and the effect of vaping device used was assessed among
61 ever vapers. Analyses controlled for demographic characteristics, use of cannabis and alcohol,
62 and survey date.

63 **Results:** Each additional puff year increased the rate ratio of respiratory symptoms by a factor of
64 11.36 (95%CI: 4.61-28.00; $p < 0.001$) for never smokers, but among current daily smokers higher
65 pack equivalent years were not associated with more respiratory symptoms (0.83; 95% CI: 0.23,
66 3.11). Among current vapers, those using pod-style devices were more likely to have more
67 respiratory symptoms (1.25; 95% CI: 1.08, 1.45) after adjusting for dose.

68 **Conclusions** Vaping is associated with an increased risk of reporting respiratory symptoms
69 among never smoking youth and non-daily ever cigarette smokers. Use of e-cigarettes among
70 non-smokers should be discouraged.

71
72 **Funding** Canadian Institutes of Health Research

73
74

75 **Introduction**

76 Cigarette smoking has long been known to be associated with poor respiratory health outcomes,
77 including lung cancer, chronic obstructive pulmonary disease (COPD), and severe asthma.¹ In
78 the past several decades, the prevalence of cigarette smoking has decreased drastically across
79 North America. Even so, it remains prevalent with an estimated 14.8% of Canadians smoking
80 cigarettes in 2019, which is slightly higher than rates of 14.1% in the United Kingdom and
81 14.0% in the United States.^{2,3,4}

82 While the use of cigarettes has become less common, electronic cigarettes (e-cigarettes) have
83 quickly gained global popularity as both smoking cessation aids as well as recreational nicotine
84 delivery devices.⁵ This rise in use has been especially prominent amongst youth, with several
85 studies observing large increases in the prevalence of youth e-cigarette use in both the United
86 States and Canada within the past decade, with 15% of youth in Canada aged 15 to 19 reporting
87 past 30-day use of e-cigarettes in 2019, compared to only 6% in 2017.^{6,7,8} Despite being initially
88 introduced as a supposedly safer alternative to cigarettes, e-cigarettes have been found to be
89 associated with some health-related harms similar to cigarettes.^{9,10} Further, the use of e-cigarettes
90 has been associated with additional harms unique to the electronic devices.¹⁰ Literature
91 surrounding the health impacts of e-cigarette use is still evolving, but existing research has
92 identified both short- and long-term respiratory harms due to e-cigarette use.¹¹ However, existing
93 research primarily includes adult samples, limiting generalizability to youth populations, which
94 differ biologically, psychologically, and sociologically. Further research is thus necessary to
95 assess the effect of vaping frequency on risk of respiratory symptoms, especially among youth
96 who are at highest risk of vaping initiation. Additionally, the association between vaping device
97 type/e-cigarette liquid flavour and respiratory symptoms must be assessed as different devices

98 provide varying doses of vapor per puff, which may impact risk of respiratory symptoms among
99 users of certain device types, even with a lower vaping frequency.

100 In addition, many individuals engage in dual use of cigarettes and e-cigarettes.^{12,13} Motivations
101 for dual use vary, with research suggesting that individuals who initiate the use of e-cigarettes
102 with the goal of smoking cessation are more likely to engage in dual use than to engage in e-
103 cigarette use alone.¹² This may be the case because smokers who use e-cigarettes as smoking
104 cessation aids may not fully transition from smoking to vaping, despite often beginning with the
105 intention to quit smoking entirely.¹²

106 Research surrounding the health impacts of the dual use of cigarettes and e-cigarettes remains
107 limited. Results from existing studies have been mixed, with some finding that dual use leads to
108 mitigated health-related harms due to the overall decrease in the use of cigarettes.^{12,13} Other
109 research has found that the potential mitigation of health-related harms as a result of switching
110 from cigarettes to e-cigarettes are negated in those who continue to smoke cigarettes alongside
111 using e-cigarettes. This may be observed as no difference in health-related harms between dual
112 users and single product users or increased harms among dual users. Notably, most of these
113 studies focus on the health-related impacts of either smoking or vaping, but not both.¹⁴⁻¹⁸ Finally,
114 much research remains inconclusive surrounding the harms associated with the dual use of
115 cigarettes and e-cigarettes, as well as with regards to how these impacts differ between
116 individuals who are solely users of either cigarettes or e-cigarettes.¹²

117 The current analysis sought to use survey data to understand better the association between e-
118 cigarette use and self-reported respiratory symptoms among youth, along with the association
119 between self-reported respiratory symptoms and e-cig dose (number of puffs per month), vaping
120 device, e-cigarette liquid flavour, and years vaped. In doing so, we seek to add to a growing body

121 of research regarding the extent of harms related to the use of e-cigarettes. Additionally, the
122 study aims to assess the interaction associated with the dual use of cigarettes and e-cigarettes on
123 respiratory symptoms. Based on current research on both vaping and smoking cigarettes, we
124 hypothesized that individuals who smoked cigarettes regularly and those who vaped regularly
125 would report more respiratory symptoms compared to non-smokers and non-vapers. We further
126 hypothesized that dual use of cigarettes and e-cigarettes would be associated with more
127 respiratory symptoms compared to vaping alone, but lower compared to cigarette smoking alone,
128 due to satiation of cravings that would decrease cigarettes smoked daily. However, this
129 assumption of decreased cigarette intake may be incorrect, as some studies reported lower levels
130 of smoking in dual users, while others reported no notable change in number of cigarettes
131 smoked, though fewer respiratory symptoms were still observed.¹⁸ To further this understanding,
132 we also considered potential confounding factors in the relationship between smoking and
133 respiratory health, including age, sex, education level, and other substance use.

134

135 **Methods**

136 **Data Source**

137 Participants were recruited from the Ontario Tobacco Research Unit Youth and Young Adult
138 Research Registration Panel November 2020 to March 2021 (Pienkowski, 2021). Panel
139 recruitment was completed via social media advertisements from August 2020 to February 2021.
140 Panel participants completed a recruitment survey and provided information for future contact.
141 From the panel, adolescents and young adults aged 16-25 living in Canada were eligible for the
142 survey. Targeted recruitment by email was used to balance the survey respondents for vaping
143 status (never, ever (at least one puff), past 30 days), smoking status (never, ever, past 30 days)

144 and age (16-18, 19-25). Participation rate was 60%. Younger females, those with higher
145 education, and those who had never used e-cigarettes or cigarettes were more likely to
146 participate. There were 3082 youth who completed the baseline survey including 396 individuals
147 reporting a diagnosis of asthma. The University of Toronto Research Ethics Board provided
148 ethics approval.

149

150 **Measures**

151 The primary exposure variables was pack-equivalent years. This value was calculated
152 equivalents to the pack-years calculation for cigarettes. The number of reported puffs per day on
153 days vaped (divided by 10, the standard number of puffs in a cigarette) was multiplied by the
154 number of days vaped per month (divided by 30 to provide an average daily use). This value was
155 then divided by 20 to convert to packs (20 cigarettes per pack) and then multiplied by the
156 number of years of vaping report (current age-age at first vape).

157 The outcome variable was the self-reported occurrence of adverse respiratory symptoms. Data on
158 five respiratory symptoms were collected, with survey respondents identifying any symptoms
159 they experienced in the past four months (yes/no). The five symptoms were coughing regularly,
160 coughing up phlegm regularly, feeling out of breath from even simple chores, wheezing when
161 exerting oneself (e.g., through exercise or going up the stairs), and getting many colds
162 (specifically those that take longer to recover). The five questions were combined to form an
163 overall respiratory symptoms variable, the Canadian Lung Health Test. This measure was
164 originally validated for use in screening for COPD but comprises a set of questions routinely
165 used by clinicians to evaluate patients for respiratory disorders.¹⁹ The maximum number of

166 respiratory symptoms that could be selected by a respondent was five and the minimum number
167 of symptoms was zero.

168 Cigarette status was self reported and categorized into (never smoked a cigarette, smoked a
169 cigarette but not a current daily smoker, and daily smoker). Participants also reported number of
170 cigarettes smoked per day, and whether or not they were past month users of alcohol and
171 cannabis. Participants were asked what vaping device they had last used, and how long they had
172 been vaping at the time of survey completion. Data on demographic characteristics were also
173 collected (sex, age, education, parental status, marital status, province of residence, and race).
174 Participants also reported whether or not they had received a diagnosis of asthma.

175

176 **Statistical Analysis**

177 This analysis assessed the effect of e-cigarette use and frequency on the rate ratios of respiratory
178 symptoms, assessed via a Poisson regression model. The interaction between e-cigarette puffs
179 per day and number of cigarettes smoked per day on respiratory symptoms was also assessed. All
180 other covariates in the model were chosen based on past research. Covariates were included in
181 the analysis if they were deemed to be conceptually relevant as confounders. Covariates were
182 respondent age, sex, race, education level, race, province and history of substance-use other than
183 cigarettes or e-cigarettes.

184 An additional Poisson regression analysis was conducted which assessed effects of self-reported
185 vaping device type, vaping flavour, and number of years since starting vaping on respiratory
186 symptoms among current e-cigarette users. Analyses were performed using Stata/IC 16.1.

187

188

189 **Results**

190 Descriptive statistics were calculated for all variables included in the Poisson regression model
191 and outlined in Table 1. The average age of participants included in this analysis was 19.6 years
192 (SD=2.7), ranging from 16 to 25 years. The majority of respondents were white (n=2270,
193 73.7%) and 80.6% were female (n=2456). 396 individuals reporting a diagnosis of asthma.
194 Descriptive statistics for all analyzed variables can be seen in Table 1.

195
196 Half of respondents reported either never vaping or not currently vaping at all (n=1554, 50.4%),
197 10.5% reported less than monthly vaping (n=323), 5.4% reported vaping monthly (n=165), 5.8%
198 vaped weekly (n=178), and 28.0% reported vaping daily (n=862). The average number of
199 cigarettes smoked per day among ever-smokers in the sample was 4.4 (SD=7.2), while the daily
200 average among exclusive current daily smokers was 9.8 (SD=11.8) and the daily average among
201 current daily dual users was 5.7 (SD=5.9) cigarettes per day. Never smokers who vaped had
202 lower numbers of puffs per day, number of days vaped per month, and number of years vaped
203 than ever smokers and daily smokers (Table 2).

204
205 Table 3 outlines the percentage distribution of respiratory symptoms by smoking and vaping
206 status. Half of respondents reported zero respiratory symptoms (51.5%). Of never-users, non-
207 daily and daily e-cigarette users, the highest proportion of respondents reported zero symptoms
208 (65.8%, 56.8%, and 34.2%, respectively), compared to the highest proportion of daily smokers
209 who reported experiencing one respiratory symptom (23.2%), and the highest proportion of dual-
210 users who reported experiencing two respiratory symptoms (25.0%). While for three of the five
211 symptoms the majority of participants did not report experiencing the symptom, regardless of

212 smoking or vaping status, the majority of daily smokers, regardless of vaping status, did report
213 coughing regularly in the last four months (65.6% of daily smokers, non-vapers; 57.1% of daily
214 smokers, daily vapers), and the majority of daily smokers, non-vapers reported coughing up
215 phlegm regularly (52.2%). Additionally, daily smokers, daily vapers, and daily dual-users were
216 all more likely to report experiencing any of the five symptoms compared to non-daily or never-
217 users of either cigarettes or e-cigarettes. Daily smokers were also more likely to report
218 experiencing any symptoms compared to daily vapers. Dual users had lower rates of reporting of
219 all symptoms compared to daily smoking alone, especially when looking at wheezing (35.8% of
220 dual-users, compared to 46.1% of daily smokers) ($p < 0.05$ for cold frequency and duration,
221 $p < 0.001$ for all other respiratory symptoms and total number of symptoms).

222
223 Each additional puff year increased the rate ratio of respiratory symptoms by a factor of 11.36
224 (95%CI: 4.61-28.00; $p < 0.001$) for never smokers and ever smokers (2.79; 95% CI: 1.69, 4.61),
225 but among current daily smokers higher pack equivalent years were not associated with more
226 respiratory symptoms (0.83; 95% CI: 0.23., 3.11) (Table 4). Test of interactions were
227 statistically significant ($p < 0.001$) (See supplemental files).

228
229 Figure 1 depicts the modelled relationship between pack equivalent years and number of
230 respiratory symptoms, by cigarette smoking status. Never smokers with no vaping history have
231 fewer respiratory symptoms than those who have smoked with average number of symptoms of
232 respiratory symptoms approaches the level seen in daily smokers after 0.5 puff year. Daily
233 smokers do not demonstrate increasing symptoms with greater pack equivalent years.

234

235 Among current vapers, those using pod-style devices were more likely to have more respiratory
236 symptoms (1.25; 95% CI: 1.08, 1.45) after adjusting for dose (See supplemental files).

237

238 **Discussion**

239 Our analysis found that use of e-cigarettes was associated with increased rate of respiratory
240 symptoms, and that the greater the frequency of vaping the higher the number of symptoms.

241

242 Unsurprisingly, higher amounts of cigarette smoking were also strongly associated with more
243 respiratory symptoms. This population of youth and young adults reflects a lighter smoking
244 sample than would be found among all adults. Exclusive daily smokers reported smoking an
245 average of 9.8 cigarettes per day, while dual users reported smoking an average of 5.7 cigarettes
246 per day, which is notably lower than previous research that showed an average daily cigarette
247 consumption among Canadian daily smokers of 13.7 in 2017.²⁰ Despite this level of smoking,
248 elevated respiratory symptoms were higher in smokers than non-smokers indicating the
249 dangerousness of cigarettes. Similarly, this population of youth and young adults have limited
250 number of years of experience vaping, but despite this, increased frequency and length of time
251 vaping was associated with increased numbers of respiratory symptoms that can, with sufficient
252 dose, approach the short term respiratory harms associated with smoking cigarettes.

253

254 With regards to dual use, however, we observed that those individuals who vaped daily and
255 smoked cigarettes daily did not demonstrate additional risk from vaping. That is, dual users
256 reported notably high levels of respiratory symptoms compared to non-users of both cigarettes
257 and e-cigarettes, though an increase in e-cigarette puffs resulted in a marginal decrease in rate of

258 respiratory symptoms. These results are congruent with existing studies that reported health
259 benefits of dual use compared to exclusive cigarette smoking.^{12,13,15,17} However, due to the high
260 baseline of respiratory symptoms among cigarette smokers, it is difficult to ascertain the true
261 benefit of dual-use without longitudinally monitoring changes in smoking behaviours of
262 exclusive smokers that become dual users, to determine the mechanism behind this decrease in
263 symptoms.

264

265 This study also builds on these results via the inclusion of a vaping-only group, as well as via the
266 inclusion of youth participants, which allows for more specified results and interpretations.
267 Though the specification of age may limit generalizability to the overall population, it also
268 allows for increased accuracy and reliability in constructing prevention and treatment plans for
269 youth. Additional studies that monitor exact number of cigarettes smoked and e-cigarette puffs
270 among single users versus dual users are needed to confirm this.

271 Those who vaped pod like devices reported higher levels of symptoms after controlling for puff
272 year. This finding is consistent with previous results wherein adolescents reported experiencing
273 worse respiratory symptoms when using specific vape brands and products, particularly JUUL, a
274 pod device with a nicotine salt liquid.²¹ As was expected, subjects with a longer history of vaping
275 experienced more respiratory symptoms than newer vapers, as they have likely inhaled a larger
276 number of total puffs.

277

278 **Limitations**

279 While this analysis provided insight into the association between the dual use of vaping and
280 smoking on respiratory health symptoms, there are limitations that should be noted. First, there

281 are substantial limitations to the generalizability of this survey due to the purposive online
282 sampling. The high participation of females suggests that the results are more robust for young
283 females. While the anonymous, online nature of the survey may encourage honesty, there is also
284 a risk of recall bias, as participants may incorrectly recall their use behaviours or respiratory
285 symptoms, either unintentionally or intentionally, especially if they are advocates for smoking or
286 vaping. Additional studies that include physical assessments of subjects' respiratory health and
287 biomarkers of smoking/vaping are necessary to achieve more accurate and reliable results.
288 The cross-sectional nature of these data also presents some limitations with regards to the
289 conclusions that can be drawn from our analysis. Because survey respondents were asked about
290 their use of cigarettes and e-cigarettes simultaneously and retrospectively, it is unclear how
291 patterns of use changed over the lifecourse and how these reported symptoms may or may not
292 lead to medical diagnosis of disease long term.

293

294 **Conclusion**

295 This study documented a potential correlation between vaping and an increase in respiratory
296 symptoms. A secondary finding was an interaction between dual use of cigarettes and e-
297 cigarettes and a decreased risk of respiratory symptoms compared to cigarette smoking alone,
298 which exhibited a higher baseline of symptoms. Further longitudinal research using physical
299 health assessments and biomarkers is necessary to explore this association further.

300

301 **Acknowledgements**

302 Dr. Eissenberg is a paid consultant in litigation against the tobacco industry and also the
303 electronic cigarette industry and is named on one patent for a device that measures the puffing
304 behavior of electronic cigarette users and on another patent for a smartphone app that determines
305 electronic cigarette device and liquid characteristics. Other authors have no disclosures to report.
306 The CSTP is supported by grant number U54DA036105 from the National Institute on Drug
307 Abuse of the National Institutes of Health and the Center for Tobacco Products of the U.S. Food

308 and Drug Administration. The content of this message is solely the responsibility of the author
309 and does not necessarily represent the views of the NIH or the FDA The cohort study was funded
310 by CIHR. The funding sources had no role in the study design, collection, analysis, and
311 interpretation of data, writing the report and the decision to submit the report for publication.

References

- 1 Centres for Disease Control and Prevention. Health effects of cigarette smoking. 2020. Available from: https://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/effects_cig_smoking/index.htm
- 2 Statistics Canada. *Table 13-10-0096-10 Smokers, by age group*. Retrieved from <https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310009610>
- 3 Office for National Statistics. Adult smoking habits in the UK: 2019. 2020. Accessed July 2021.
- 4 Cornelius ME, Wang TW, Jamal A, Loretan CG, Neff LJ. Tobacco product use among adults — United States, 2019. *MMWR Morb Mortal Wkly Rep* 2020;69:1736–1742.
- 5 Fatus MC, Smith TT, Squeglia LM. The rise of e-cigarettes, pod mod devices, and JUUL among youth: factors influencing use, health implications, and downstream effects. *Drug Alcohol Depend* 2019;201:85–93.
- 6 Hammond D, Reid JL, Rynard VL, et al. Prevalence of vaping and smoking among adolescents in Canada, England, and the United States: repeat national cross sectional surveys. *BMJ* 2019;20:365.
- 7 Government of Canada. Canadian Tobacco and Nicotine Survey (CTNS): Summary of Results for 2019. Accessed February 16, 2021.
- 8 Government of Canada. Canadian Tobacco Alcohol and Drugs (CTADS): Summary of Results for 2017. Accessed February 15, 2021.
- 9 Franck C, Budlovsky T, Windle SB, Filion KB, Eisenberg MJ. Electronic cigarettes in North America: history, use, and implications for smoking cessation. *Circulation* 2014;129(19):1945–52.
- 10 Krishnasamy VP, Hallowell BD, Ko JY, et al. Update: characteristics of a nationwide outbreak of e-cigarette, or vaping, product use–associated lung injury—United States, August 2019–January 2020. *MMWR Morb Mortal Wkly Rep* 2020;69(3):90.
- 11 Miyashita L, Foley G. E-cigarettes and respiratory health: the latest evidence. *J Physiol* 2020;598(2):5027–38.
- 12 Robertson L, Hoek J, Blank ML, Richards R, Ling P, Popova L. Dual use of electronic nicotine delivery systems (ENDS) and smoked tobacco: a qualitative analysis. *Tob control* 2019;28(1):13–9.
- 13 Owusu D, Huang J, Weaver SR, et al. Patterns and trends of dual use of e-cigarettes and cigarettes among US adults, 2015–2018. *Prev Med Rep* 2019;16:101009.
- 14 Osei AD, Mirbolouk M, Orimoloye OA, et al. Association between e-cigarette use and cardiovascular disease among never and current combustible-cigarette smokers. *Am J Med* 2019;132(8):949–54.
- 15 Parekh T, Pemmasani S, Desai R. Risk of stroke with E-cigarette and combustible cigarette use in young adults. *Am J Prev Med* 2020;58(3):446–52.
- 16 Wang JB, Olgin JE, Nah G, et al. Cigarette and e-cigarette dual use and risk of cardiopulmonary symptoms in the Health eHeart Study. *PLoS One* 2018;13(7):e0198681.
- 17 Abafalvi L, Péntzes M, Urbán R, Foley KL, Kaán R, Kispélyi B, Hermann P. Perceived health effects of vaping among Hungarian adult e-cigarette-only and dual users: a cross-sectional internet survey. *BMC Public Health* 2019;19(1):1–0.
- 18 Cobb CO, Foulds J, Yen MH, et al. Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, controlled trial. *Lancet Respir Med* 2021; 1-11.
- 19 Robitaille C, Dajczman E, Hirsch AM, et al. Implementation of a targeted screening program to detect airflow obstruction suggestive of chronic obstructive pulmonary disease within a presurgical screening clinic. *Can Respir J*. 2015;22(4):209-214.
- 20 Canadian Tobacco Use Monitoring Survey, 1999-2012; Canadian Tobacco, Alcohol and Drugs Survey, 2013, 2015, 2017. Accessed July 2021.
- 21 Kechter A, Schiff SJ, Simpson KA, et al. Young adult perspectives on their respiratory health symptoms since vaping. *Subst Abuse* 2020;1–13.
- 22 Canadian Tobacco, Alcohol and Drugs Survey (CTADS), 2017

Tables

Table 1. Demographics for all variables included in the multivariable linear regression model

| | Total | Never-use of both smoking and vaping | Non-daily ever-use of either smoking or vaping | Daily vaping, non-daily/never smoking | Daily smoking, non-daily/never vaping | Daily vaping, daily smoking |
|---|---------------|--------------------------------------|--|---------------------------------------|---------------------------------------|-----------------------------|
| | N=3,082 | N=825 | N=1,303 | N=820 | N=92 | N=42 |
| Age | 19.6 (2.7) | 18.8 (2.6) | 20.1 (2.8) | 19.6 (2.5) | 21.6 (2.6) | 19.6 (2.5) |
| 16-19 | 1,689 (54.8%) | 561 (68.0%) | 634 (48.7%) | 448 (54.6%) | 22 (23.9%) | 24 (57.1%) |
| 20-25 | 1,393 (45.2%) | 264 (32.0%) | 669 (51.3%) | 372 (45.4%) | 70 (76.1%) | 18 (42.9%) |
| Sex | | | | | | |
| Male | 593 (19.4%) | 116 (14.2%) | 219 (17.0%) | 227 (28.0%) | 17 (18.9%) | 14 (33.3%) |
| Female | 2,456 (80.6%) | 701 (85.8%) | 1,071 (83.0%) | 583 (72.0%) | 73 (81.1%) | 28 (66.7%) |
| Race | | | | | | |
| White | 2,270 (73.7%) | 494 (59.9%) | 983 (75.4%) | 682 (83.2%) | 78 (84.8%) | 33 (78.6%) |
| Black | 62 (2.0%) | 22 (2.7%) | 32 (2.5%) | 8 (1.0%) | 0 (0.0%) | 0 (0.0%) |
| Chinese | 201 (6.5%) | 109 (13.2%) | 72 (5.5%) | 20 (2.4%) | 0 (0.0%) | 0 (0.0%) |
| Filipino | 43 (1.4%) | 18 (2.2%) | 15 (1.2%) | 10 (1.2%) | 0 (0.0%) | 0 (0.0%) |
| Indigenous | 63 (2.0%) | 5 (0.6%) | 26 (2.0%) | 22 (2.7%) | 6 (6.5%) | 4 (9.5%) |
| Japanese | 4 (0.1%) | 0 (0.0%) | 3 (0.2%) | 1 (0.1%) | 0 (0.0%) | 0 (0.0%) |
| Korean | 19 (0.6%) | 7 (0.8%) | 7 (0.5%) | 4 (0.5%) | 1 (1.1%) | 0 (0.0%) |
| Latin-Central-South American | 55 (1.8%) | 12 (1.5%) | 29 (2.2%) | 11 (1.3%) | 2 (2.2%) | 1 (2.4%) |
| Southeast Asian | 38 (1.2%) | 21 (2.5%) | 12 (0.9%) | 5 (0.6%) | 0 (0.0%) | 0 (0.0%) |
| South Asian | 182 (5.9%) | 99 (12.0%) | 65 (5.0%) | 16 (2.0%) | 2 (2.2%) | 0 (0.0%) |
| West Asian or Arab | 56 (1.8%) | 14 (1.7%) | 30 (2.3%) | 9 (1.1%) | 1 (1.1%) | 2 (4.8%) |
| Other | 89 (2.9%) | 24 (2.9%) | 29 (2.2%) | 32 (3.9%) | 2 (2.2%) | 2 (4.8%) |
| Province | | | | | | |
| Ontario | 1,531 (49.7%) | 478 (57.9%) | 664 (51.0%) | 322 (39.3%) | 49 (53.3%) | 18 (42.9%) |
| Alberta | 496 (16.1%) | 104 (12.6%) | 203 (15.6%) | 168 (20.5%) | 15 (16.3%) | 6 (14.3%) |
| British Columbia | 483 (15.7%) | 111 (13.5%) | 210 (16.1%) | 144 (17.6%) | 10 (10.9%) | 8 (19.0%) |
| Manitoba | 116 (3.8%) | 25 (3.0%) | 52 (4.0%) | 32 (3.9%) | 6 (6.5%) | 1 (2.4%) |
| New Brunswick | 53 (1.7%) | 15 (1.8%) | 14 (1.1%) | 22 (2.7%) | 2 (2.2%) | 0 (0.0%) |
| Newfoundland and Labrador | 40 (1.3%) | 6 (0.7%) | 16 (1.2%) | 17 (2.1%) | 0 (0.0%) | 1 (2.4%) |
| Nova Scotia | 102 (3.3%) | 27 (3.3%) | 47 (3.6%) | 24 (2.9%) | 2 (2.2%) | 2 (4.8%) |
| Prince Edward Island | 16 (0.5%) | 2 (0.2%) | 5 (0.4%) | 9 (1.1%) | 0 (0.0%) | 0 (0.0%) |
| Quebec | 129 (4.2%) | 28 (3.4%) | 59 (4.5%) | 34 (4.1%) | 3 (3.3%) | 5 (11.9%) |
| Saskatchewan | 113 (3.7%) | 27 (3.3%) | 33 (2.5%) | 47 (5.7%) | 5 (5.4%) | 1 (2.4%) |
| Northwest Territories | 2 (0.1%) | 1 (0.1%) | 0 (0.0%) | 1 (0.1%) | 0 (0.0%) | 0 (0.0%) |
| Yukon | 1 (0.0%) | 1 (0.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Highest education level | | | | | | |
| Some elementary or high school | 764 (24.8%) | 286 (34.7%) | 261 (20.0%) | 185 (22.6%) | 21 (22.8%) | 11 (26.2%) |
| Completed High school | 1,489 (48.3%) | 356 (43.2%) | 604 (46.4%) | 469 (57.2%) | 40 (43.5%) | 20 (47.6%) |
| College diploma | 268 (8.7%) | 33 (4.0%) | 133 (10.2%) | 79 (9.6%) | 18 (19.6%) | 5 (11.9%) |
| University or post graduate degree | 561 (18.2%) | 150 (18.2%) | 305 (23.4%) | 87 (10.6%) | 13 (14.1%) | 6 (14.3%) |

| | | | | | | |
|--|---------------|--------------|---------------|--------------|------------|-------------|
| Marital status | | | | | | |
| Single | 2,577 (83.6%) | 768 (93.1%) | 1,058 (81.2%) | 658 (80.2%) | 63 (68.5%) | 30 (71.4%) |
| Married or living with a partner | 501 (16.3%) | 55 (6.7%) | 244 (18.7%) | 162 (19.8%) | 28 (30.4%) | 12 (28.6%) |
| Divorced/Separated/Widowed | 4 (0.1%) | 2 (0.2%) | 1 (0.1%) | 0 (0.0%) | 1 (1.1%) | 0 (0.0%) |
| Parental status | | | | | | |
| Yes | 60 (1.9%) | 4 (0.5%) | 28 (2.1%) | 20 (2.4%) | 8 (8.7%) | 0 (0.0%) |
| No | 3,022 (98.1%) | 821 (99.5%) | 1,275 (97.9%) | 800 (97.6%) | 84 (91.3%) | 42 (100.0%) |
| Vaping device type (last used) | | | | | | |
| Modifiable/tubular device | 331 (15.9%) | | 180 (15.6%) | 122 (15.2%) | 23 (25.8%) | 6 (14.3%) |
| Pod system | 1,426 (68.3%) | | 753 (65.1%) | 599 (74.9%) | 47 (52.8%) | 27 (64.3%) |
| Other¹ | 331 (15.9%) | | 224 (19.4%) | 79 (9.9%) | 19 (21.3%) | 9 (21.4%) |
| E-liquid flavour (last used) | | | | | | |
| Fruit/Candy/Dessert/Food | 1,351 (64.0%) | | 737 (62.5%) | 531 (66.5%) | 54 (60.7%) | 29 (69.0%) |
| Beverage | 35 (1.7%) | | 23 (1.9%) | 9 (1.1%) | 1 (1.1%) | 2 (4.8%) |
| Mint/Menthol | 387 (18.3%) | | 175 (14.8%) | 192 (24.0%) | 13 (14.6%) | 7 (16.7%) |
| Tobacco | 59 (2.8%) | | 23 (1.9%) | 25 (3.1%) | 8 (9.0%) | 3 (7.1%) |
| Other | 82 (3.9%) | | 42 (3.6%) | 34 (4.3%) | 5 (5.6%) | 1 (2.4%) |
| I don't know | 196 (9.3%) | | 180 (15.3%) | 8 (1.0%) | 8 (9.0%) | 0 (0.0%) |
| How often do you currently vape? | | | | | | |
| Daily or almost daily | 862 (28.0%) | 0 (0.0%) | 0 (0.0%) | 820 (100.0%) | 0 (0.0%) | 42 (100.0%) |
| Less than daily, but at least once a week | 178 (5.8%) | 0 (0.0%) | 154 (11.8%) | 0 (0.0%) | 24 (26.1%) | 0 (0.0%) |
| Less than weekly, but at least once a month | 165 (5.4%) | 0 (0.0%) | 150 (11.5%) | 0 (0.0%) | 15 (16.3%) | 0 (0.0%) |
| Less than monthly | 323 (10.5%) | 0 (0.0%) | 302 (23.2%) | 0 (0.0%) | 21 (22.8%) | 0 (0.0%) |
| Not at all | 622 (20.2%) | 0 (0.0%) | 593 (45.5%) | 0 (0.0%) | 29 (31.5%) | 0 (0.0%) |
| I have never vaped | 932 (30.2%) | 825 (100.0%) | 104 (8.0%) | 0 (0.0%) | 3 (3.3%) | 0 (0.0%) |
| Cigarettes smoked daily | 4.4 (7.2) | | 1.9 (3.0) | 3.2 (4.7) | 9.8 (11.8) | 5.7 (5.9) |
| Daily alcohol/cannabis use | 878 (28.5%) | 30 (3.6%) | 348 (26.7%) | 420 (51.2%) | 51 (55.4%) | 29 (69.0%) |
| Asthma diagnosis | 396 (12.8%) | 107 (13.0%) | 154 (11.8%) | 106 (12.9%) | 19 (20.7%) | 10 (23.8%) |

¹Other devices: disposable or rechargeable cigarette-like vaping devices, pen-like devices, and other.

Table 2. Mean number of puffs per day vaped, number of days per month vaped, number of years vaped, by smoking status (never, ever, and daily) among ever vapers (n=2150)

| | Never Smokers (n=840) | | Ever Smokers (except daily) (n=1118) | | Daily Smoker (n=192) | |
|-------------------------|--------------------------|-----|---|-----|-------------------------|-----|
| | Mean | SD | Mean | SD | Mean | SD |
| Number of puffs per day | 3.2 | 0.2 | 5.9 | 0.2 | 7.8 | 0.7 |
| Number of days vaped | 6.4 | 0.4 | 12.6 | 0.4 | 13.6 | 1 |
| Number of years vaped | 1.7 | 0.1 | 2.4 | 0.1 | 2.2 | 0.2 |

Table 3: Descriptive statistics of percentage of participants with respiratory symptoms by smoking and vaping status

| | Total | Never-use of both smoking and vaping | Non-daily ever-use of either smoking or vaping | Daily vaping, non-daily/never smoking | Daily smoking, non-daily/never vaping | Daily vaping, daily smoking | p-value |
|---|---------------|--------------------------------------|--|---------------------------------------|---------------------------------------|-----------------------------|---------|
| | N=3,082 | N=825 | N=1,303 | N=820 | N=92 | N=42 | |
| Number of respiratory symptoms N= 2,973 | | | | | | | <0.001 |
| 0 | 1,531 (51.5%) | 534 (65.8%) | 712 (56.8%) | 266 (34.2%) | 12 (13.3%) | 7 (17.5%) | |
| 1 | 683 (23.0%) | 168 (20.7%) | 277 (22.1%) | 209 (26.9%) | 21 (23.3%) | 8 (20.0%) | |
| 2 | 425 (14.3%) | 76 (9.4%) | 166 (13.2%) | 156 (20.1%) | 17 (18.9%) | 10 (25.0%) | |
| 3 | 186 (6.3%) | 21 (2.6%) | 66 (5.3%) | 77 (9.9%) | 17 (18.9%) | 5 (12.5%) | |
| 4 | 111 (3.7%) | 11 (1.4%) | 23 (1.8%) | 53 (6.8%) | 16 (17.8%) | 8 (20.0%) | |
| 5 | 37 (1.2%) | 1 (0.1%) | 10 (0.8%) | 17 (2.2%) | 7 (7.8%) | 2 (5.0%) | |
| Over the past 4 months, did you cough regularly? N=2,999 | | | | | | | <0.001 |
| Yes | 686 (22.9%) | 81 (9.9%) | 207 (16.4%) | 315 (40.1%) | 59 (65.6%) | 24 (57.1%) | |
| Over the past 4 months, did you cough up phlegm regularly? N=2,996 | | | | | | | <0.001 |
| Yes | 509 (17.0%) | 67 (8.2%) | 170 (13.4%) | 206 (26.3%) | 47 (52.2%) | 19 (45.2%) | |
| Over the past 4 months, did even simple chores make you short of breath? N=2,992 | | | | | | | <0.001 |
| Yes | 629 (21.0%) | 94 (11.5%) | 231 (18.3%) | 242 (30.9%) | 41 (45.6%) | 21 (51.2%) | |
| Over the past 4 months, did you wheeze when you exert yourself? N=2,995 | | | | | | | <0.001 |
| Yes | 673 (22.5%) | 135 (16.5%) | 254 (20.1%) | 223 (28.4%) | 43 (47.8%) | 18 (43.9%) | |
| Over the past 4 months, did you get many colds and do your colds usually last longer than your friends' colds? N=2,999 | | | | | | | <0.05 |
| Yes | 247 (8.2%) | 61 (7.5%) | 97 (7.6%) | 70 (8.9%) | 15 (16.7%) | 4 (9.8%) | |


Table 4. Poisson regression summary table of rate ratios for effects of vaping and smoking frequencies on respiratory symptoms stratified by smoking status)

| | Non Smokers | Ever Smokers | Daily Smokers |
|-----------------------------|--------------------------|------------------------|---------------------|
| Respiratory symptoms | | | |
| Pack equivalent years | 11.36*** [4.61,28.00] | 2.79*** [1.69,4.61] | 0.84 [0.23,3.11] |
| <i>N</i> | 1445 | 1059 | 156 |

²Exponentiated coefficients adjusted for respondent age, sex, education, marital status, parental status, registration date, other daily drug use, province, and race, those who reported a diagnosis of asthma are excluded. Full tables with covariates available in Supplementary Materials (Supplementary Table 1).

* p<0.05, ** p<0.01, *** p<0.001

Figure 1. Modelled number of respiratory symptom by e-cigarette pack equivalent years by smoking status among Canadian youth (16-25) (n=2660)



Figure